Literature DB >> 20466105

Primary closure of stoma site wounds after ostomy takedown.

Dawn M Harold1, Eric K Johnson, Julie A Rizzo, Scott R Steele.   

Abstract

BACKGROUND: Ostomy reversal is considered a contaminated surgery and, thus, primary closure is believed to increase infection. Various closure techniques have been described and postulated to be superior to primary closure in regards to decreasing stoma site wound infections. The literature has varied in its support for this hypothesis.
METHODS: A retrospective review was performed evaluating several variables including stomal closure method, patient demographics, steroid/immunosuppressant use, chemotherapy or radiation, perioperative antibiotics, and surgical indication to determine whether there was any association with the development of wound infections.
RESULTS: Of 75 patients undergoing ostomy reversal, delayed primary closure/packing/secondary intention was used in 49 (65%), and 26 underwent primary closure (35%). Four patients (5.3%) developed stoma site infections; all had delayed primary closure or packing of their wound (P = .39). No variable was associated significantly with an increased risk of stoma site wound infections.
CONCLUSIONS: Primary closure does not increase the rate of infection. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20466105     DOI: 10.1016/j.amjsurg.2010.01.008

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Reversal of Hartmann's procedure utilizing single-port laparoscopy: an attractive alternative to laparotomy.

Authors:  Stefan H E M Clermonts; Winanda M J de Ruijter; Yu-Ting T van Loon; Dareczka K Wasowicz; Joos Heisterkamp; John K Maring; David D E Zimmerman
Journal:  Surg Endosc       Date:  2015-07-15       Impact factor: 4.584

2.  The Effectiveness of Contralateral Drainage in Reducing Superficial Incisional Surgical Site Infection in Loop Ileostomy Closure: Prospective, Randomized Controlled Trial.

Authors:  Anna Serracant; Xavier Serra-Aracil; Laura Mora-López; Anna Pallisera-Lloveras; Sheila Serra-Pla; Alba Zárate-Pinedo; Salvador Navarro-Soto
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

3.  Risk factor for the development of surgical site infection following ileostomy reversal: a single-center report.

Authors:  Shuangming Lin; Dongbo Xu; Yibin Zhu; Jianxun Chen
Journal:  Updates Surg       Date:  2022-08-24

4.  Factors predicting stomal wound closure infection rates.

Authors:  N Mirbagheri; J Dark; S Skinner
Journal:  Tech Coloproctol       Date:  2012-10-18       Impact factor: 3.781

5.  The influence of nutritional assessment on the outcome of ostomy takedown.

Authors:  Min Sang Kim; Ho Kun Kim; Dong Yi Kim; Jae Kyun Ju
Journal:  J Korean Soc Coloproctol       Date:  2012-06-30

6.  Temporary closure of colostomy with suture before colostomy takedown improves the postoperative outcomes.

Authors:  Wan-Hsiang Hu; Ko-Chao Lee; Kai-Lung Tsai; Hong-Hwa Chen
Journal:  Int J Colorectal Dis       Date:  2017-11-22       Impact factor: 2.571

Review 7.  Prevalence and Predictive Factors for Nosocomial Infection in the Military Hospitals: A Systematic Review and Meta-Analysis.

Authors:  Ehsan Teymourzadeh; Mohamadkarim Bahadori; Hamed Fattahi; Hossein Ali Rahdar; Sima Mirzaei Moghadam; Azad Shokri
Journal:  Iran J Public Health       Date:  2021-01       Impact factor: 1.429

8.  Purse-String Versus Linear Conventional Skin Wound Closure of an Ileostomy: A Randomized Clinical Trial.

Authors:  Mina Alvandipour; Babak Gharedaghi; Hamed Khodabakhsh; Mohammad Yasin Karami
Journal:  Ann Coloproctol       Date:  2016-08-31

9.  Effect of closed incision negative pressure wound therapy on incidence rate of surgical site infection after stoma reversal: a pilot study.

Authors:  Maciej Borejsza-Wysocki; Adam Bobkiewicz; Wojciech Francuzik; Lukasz Krokowicz; Dominik Walczak; Jacek Szmeja; Tomasz Banasiewicz
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-05-25       Impact factor: 1.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.